Clinical Study | Office of Clinical Research

Keychain- Phase II Randomized Trial Of Radiotherapy With Concurrent And Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy In Patients With Advanced/Intermediate-Risk P16+ Head And Neck Squamous Cell Carcinoma

Posted Date: Apr 23, 2020

Investigator: Trisha Wise-Draper
Specialties: Cancer, Head and Neck Cancer, Oncology
Type of Study: Drug

The primary goal of this study is to test the hypothesis that pembrolizumab improves progression free survival (PFS) in this population compared to standard of care (RT plus cisplatin)

Criteria:

To Be Eligible: Must Have Diagnoses Of Hnscc, Adequate Organ Function, No Prior Malignancy Within 3 Years, No Prior Therapy For Study Cancer, No Hypersensitivity To Study Drugs Or Excipients, No Active Severe Co-Morbidity

Keywords:

Head And Neck Cancer, Hnscc

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List